Primary source: What is an Early Alert?
Affected customers must now destroy the entire convenience kit rather than only removing and discarding the affected component.
The contamination poses serious health risks, including potential systemic infection and sepsis, which can lead to severe illness or death.
Customers are required to quarantine affected kits, complete response forms, and destroy the kits. Notification must also be sent to distributors who should inform their customers of these updated actions.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Customers are required to quarantine affected kits, complete response forms, and destroy the kits. Notification must also be sent to distributors who should inform their customers of these updated actions.
Avid Medical has issued an Early Alert regarding certain non-sterile IV Start Kits that may be contaminated with Aspergillus penicillioides. Affected customers are instructed to remove these kits from use, quarantine, and destroy the entire kit. This action follows previous notifications and emphasizes the serious health risks associated with potential contamination.
What changed: Affected customers must now destroy the entire convenience kit rather than only removing and discarding the affected component.
Why it matters: The contamination poses serious health risks, including potential systemic infection and sepsis, which can lead to severe illness or death.
Practical implication: Customers are required to quarantine affected kits, complete response forms, and destroy the kits. Notification must also be sent to distributors who should inform their customers of these updated actions.
Published from the regulator source ingestion pipeline after PV impact triage.
Monitor and evaluate the drug misuse trends and health impacts associated with ketamine, focusing on the increase in seizures as part of public health and law enforcement strategies.
Implement the updated product information by November 5, 2026, ensuring that all labeling and documentation includes the new warnings and risk profiles.
Implement new labeling requirements for choline salicylate products by November 5, 2026, including specific warnings as outlined.
The marketing authorization holder must submit amended product information reflecting the new safety guidelines by October 9, 2026, with translations due by August 10, 2026.
